AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• The PTEN-AKT1 signaling pathway is crucial in human cancers.
• Loss-of-function PTEN mutations and gain-of-function AKT1 mutations are common in cancer.

Purpose of the Study:

• To investigate the role of PTEN deficiency and AKT1 activation in regulating PDGFRα expression.
• To elucidate the molecular mechanisms linking PTEN loss to PDGFRα upregulation.
• To evaluate PDGFRα as a therapeutic target in PTEN-deficient cancers.

Main Methods:

• Studies on Pten-/- mouse embryonic fibroblasts and human cancer cell lines.
• Analysis of hepatic tissues from Pten conditional knockout mice and human cancer tissues.
• Investigation of the AKT1-CREB signaling cascade and CREB binding to the PDGFRα promoter.
• Tumorigenicity assays using Pten-null cells in nude mice.
• Correlation analysis between PI3K-AKT pathway, PDGFRα expression, and patient survival.
• Combination treatment studies using AKT and PDGFR inhibitors.

Main Results:

• PTEN deficiency or AKT1 activation potentiates PDGFRα expression via the AKT1-CREB cascade.
• CREB directly binds to and transactivates the PDGFRα gene promoter.
• PDGFRα depletion attenuates the tumorigenicity of Pten-null cells.
• PDGFRα expression positively correlates with PI3K-AKT signaling and predicts poor patient survival.
• Combination therapy with AKT and PDGFR inhibitors shows synergistic anti-tumor effects.

Conclusions:

• The AKT1-CREB-PDGFRα signaling pathway is activated by PTEN deficiency and contributes to tumor growth.
• Targeting this pathway, particularly PDGFRα, holds promise for treating PTEN-deficient cancers.
• Combined inhibition of AKT and PDGFR may offer synergistic therapeutic benefits.